Jorge Conde co-founded a synthetic biology company with renowned genomics pioneer George Church at Harvard, giving him rare founder experience in cutting-edge genomics before becoming a venture capitalist. He regularly hosts Andreessen Horowitz podcasts where he interviews leading scientists and CEOs, positioning him as a public educator who bridges academic science with entrepreneurial ecosystems.

• Focus on the intersection of artificial intelligence and biology to manage complexity and accelerate discovery. He consistently highlights companies using AI to automate workflows or democratize access to advanced models, such as the seed investment in Phylo to build an AI scientist or Boltz to bring biomolecular AI to labs of all sizes.
• Interest in the evolution of gene therapy, specifically regarding delivery mechanisms and regulatory frameworks. He frequently discusses the challenge of delivering genetic payloads, illustrated by his support for Dyno Therapeutics and their AI-designed capsids, and proposes new regulatory ideas like treating genetic editing as an interventional procedure rather than a standard therapeutic product.
• Advocacy for modernizing the FDA and drug approval processes through platform technologies. He draws parallels between the tech industry and biotech regulation, suggesting that the industry should move toward a reusable rocket model where prior data can speed up future approvals, rather than starting from scratch for every new drug.
• Concern with operational bottlenecks in the biopharma industry, such as clinical trial recruitment and manufacturing. He contrasts the speed of drug development in China versus the US to highlight the need for better technology in patient recruitment and calls for automated labs that offer both scale and flexibility, likening the need to autonomous vehicles rather than rigid subway systems.
• Support for mission-driven founders and open science, particularly those motivated by personal connections to rare diseases. He shares stories that blend high-level chemistry with personal determination, such as a collaboration between a Nobel laureate and a parent trying to cure their daughter's rare genetic condition, emphasizing that the highest aim of the field is to fix what is broken.